Study of three study drugs for kidney failure patients on dialysis
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests three experimental antibodies given to people with end-stage kidney disease who are on hemodialysis. It aims to see if these drugs are safe and how they affect blood clotting in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have end-stage kidney disease and regularly attend hemodialysis 3 times a week.
- You receive standard heparin during each dialysis session and have tolerated it before.
- You have adequate vascular access for dialysis.
- You have been stable with no hospital stays in the past 30 days.
- You have not had major bleeding in the last 3 months.
- You are not currently taking blood thinners like warfarin or other oral anticoagulants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a newer type of dialysis called hemodiafiltration with standard hemodialysis to see if it improves certain health measures in people with end-stage kidney disease. It may help determine which method works better for long-term treatment.
This study tests how a new drug called CSL300 (clazakizumab) works in the body of people with end-stage kidney disease who are on dialysis. Researchers want to understand if it's safe and how your body processes it.
This study tests different treatments for people with advanced kidney disease, including those on dialysis or with a kidney transplant. It aims to find better ways to manage the condition and improve outcomes.
This study tests an experimental drug called KN060, given to people with end-stage kidney disease on dialysis, to see if it is safe and helps with blood clotting. It may be an option if you are on stable dialysis and not at high risk for bleeding.
This study tests whether dialysis can be done safely without using heparin (a blood thinner) in people with end-stage kidney disease. If successful, it could reduce the need for blood-thinning medications and their associated risks.
This trial tests whether adding a special filter called pHA130 to your regular dialysis treatments can better remove certain waste products from your blood and improve your quality of life. It's for people who have been on dialysis for at least 3 months and meet a few health requirements.
Hear when a new End-Stage Kidney Disease (ESKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.